A Description of the THRIVE (The Study of Host-Bacterial Relationships and Immune Function in Different Vaginal Environments) Bacterial Vaginosis Observational Study
- PMID: 39362489
- DOI: 10.1016/j.jogc.2024.102667
A Description of the THRIVE (The Study of Host-Bacterial Relationships and Immune Function in Different Vaginal Environments) Bacterial Vaginosis Observational Study
Abstract
Objectives: Bacterial vaginosis (BV) contributes to poor reproductive health and is characterized by a displacement of Lactobacillus in the vaginal microbiome. However, treatment for BV is limited to antibiotics and half of the women treated experience recurrence within a year. THRIVE (The Study of Host-Bacterial Relationships and Immune Function in Different Vaginal Environments) is a prospective study in Winnipeg, Manitoba, Canada, which is designed to capture the daily variation of the microbiome and host mucosal immunity during treatment. The objective of this study is to identify host and bacterial factors that associate with vaginal microbiome stability to better inform therapeutic interventions.
Methods: Women treated for BV, and controls, are followed for 6 months collecting daily vaginal swabs and monthly questionnaires. Comprehensive mucosal sampling, including swabs, cytobrushes, biopsies, and blood are collected at baseline, months 1 and 6 post-enrolment.
Results: We performed analysis on the first 52 participants, (19 BV+, 33 BV-). Molecular profiling by 16s RNA sequencing showed 20 women with non-Lactobacillus-dominant microbiomes and 32 with Lactobacillus-dominant microbiomes, with increased microbial diversity in non-Lactobacillus-dominant microbiomes (P = 3.1E-05). A pilot analysis in 2 participants demonstrates that multi-omics profiling of self-collected daily swabs provides high-quality data identifying 73 bacterial species, 1773 mucosal proteins and 117 metabolites. Initial flow cytometry analysis showed an increased cluster of differentiation (CD)4+ T cells and neutrophil activation (CD11b+CD62Lneg/dim) in the positive participant at baseline, while after treatment these shifted and resembled the control participant.
Conclusions: This study provides a framework to comprehensively investigate the kinetics of vaginal mucosal microbiome alterations, providing further insight into host and molecular features predicting BV recurrence.
Keywords: bacterial vaginosis; cohort studies; microbiome; mucosal immunity; reproductive health.
Copyright © 2024 The Author. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial.Lancet Microbe. 2025 Jun;6(6):101037. doi: 10.1016/j.lanmic.2024.101037. Epub 2025 Apr 4. Lancet Microbe. 2025. PMID: 40194532 Free PMC article. Clinical Trial.
-
Temporal dynamics of the vaginal microbiome and host immune markers before, during, and after metronidazole treatment for bacterial vaginosis.mSystems. 2025 Jul 22;10(7):e0038025. doi: 10.1128/msystems.00380-25. Epub 2025 Jul 3. mSystems. 2025. PMID: 40607829 Free PMC article.
-
Douching cessation and molecular bacterial vaginosis: a reanalysis of archived specimens.Sex Transm Infect. 2023 May;99(3):156-161. doi: 10.1136/sextrans-2022-055459. Epub 2022 May 30. Sex Transm Infect. 2023. PMID: 35636931 Free PMC article.
-
Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.NPJ Biofilms Microbiomes. 2025 Jul 1;11(1):115. doi: 10.1038/s41522-025-00748-0. NPJ Biofilms Microbiomes. 2025. PMID: 40595711 Free PMC article. Review.
-
Risks associated with bacterial vaginosis in infertility patients: a systematic review and meta-analysis.Hum Reprod. 2013 Jul;28(7):1809-15. doi: 10.1093/humrep/det096. Epub 2013 Mar 29. Hum Reprod. 2013. PMID: 23543384
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials